⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL135847 | 0.95 | — | — | |
| SCHEMBL6281958 | 0.80 | — | — | |
| SCHEMBL7600038 | 0.80 | — | — | |
| SCHEMBL18626383 | 0.80 | — | — | |
| SCHEMBL19986846 | 0.79 | LMNA (0.30) | — | |
| SCHEMBL6276973 | 0.78 | — | — | |
| SCHEMBL2410182 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL7602327 | 0.76 | — | — | |
| SCHEMBL3505709 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL20969327 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | claimed |
| CN-113827893-A | Fire extinguishing device and method for battery compartment | 国网湖南省电力有限公司 | 2021-12-24 | — | — | CN | claimed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | claimed |
| US-20210060040-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | claimed |
| US-10632134-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | claimed |
| US-20200078358-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | claimed |
| CN-110709085-A | Compounds and methods for treating visceral pain | 艾尼纳制药公司 | 2020-01-17 | — | — | CN | claimed |
| US-20180354907-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2018-12-13 | — | — | US | claimed |
| US-8772300-B2 | Phenyl or pyridinyl-ethynyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | claimed |
| EP-2699547-A1 | 5-(PHENYL/PYRIDINYL-ETHINYL)-2-PYRIDINE/ 2-PYRIMIDINE-CARBORXAMIDES AS MGLUR5 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2014-02-26 | — | — | EP | claimed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| WO-2012143340-A1 | 5-(PHENYL/PYRIDINYL-ETHINYL)-2-PYRIDINE/ 2-PYRIMIDINE-CARBORXAMIDES AS MGLUR5 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-26 | — | — | WO | claimed |
| US-20120270852-A1 | PHENYL OR PYRIDINYL-ETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-25 | — | — | US | claimed |
| WO-2012116278-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-0931082-A4 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 1999-11-17 | — | — | EP | claimed |
| EP-0931082-A1 | NODULISPORIC ACID DERIVATIVES | Merck & Co., Inc. (a New Jersey corp.) (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998012196-A1 | NODULISPORIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |